Neuro-Oncology News

A dramatic rise in global incidence of early-onset cancers over the past 30 years may be related in part to increased exposure to risk factors at a young age, according to study results published in Nature Reviews Clinical Oncology,

The addition of an autologous tumor lysate-loaded dendritic vaccine to standard care extended OS among certain patients with glioblastoma, according to results of a prospective phase 3 trial published in JAMA Oncology.

Cancer death rates declined broadly between 2015 and 2019 in the United States as overall incidence remained generally stable, according to the Annual Report to the Nation on the Status of Cancer.

An artificial intelligence model appeared to predict the likelihood of unplanned hospitalizations during chemoradiation therapy among a cohort of patients with various cancer types.

The FDA approved bevacizumab-adcd for treatment of six cancer types, according to a press release from the biosimilar’s manufacturer.

A novel multicancer early detection blood test identified a common signal for more than 50 cancer types and predicted where the signal originated in the body among individuals with undiagnosed cancer.

President Joe Biden today detailed two new initiatives related to his administration’s cancer moonshot.

September is Childhood Cancer Awareness Month.

The FDA granted orphan drug designation to WP1122 for the treatment of glioblastoma multiforme, according to a press release from the agent’s manufacturer.

Ashish Shah, MD, has been named director of clinical trials and translational research at Sylvester Comprehensive Cancer Center’s Brain Tumor Initiative at University of Miami Miller School of Medicine.